When: Daily close below $63.80 (below capitulation low $63.96 and 200 SMA at $65.26)

Then: Exit position

When: MO/SPY ratio daily close below prior 10-day low

Then: Re-evaluate position

HOLD with defensive position sizing; do not add above $70.50; maintain stop at $68.20; collect dividend rather than chase momentum breakout

• FCF coverage of 1.30x ($9.07B FCF vs $6.96B dividend) provides only ~$2B buffer for capex, debt service, and working capital—described as "technically true, materially insufficient"
• Dividend exceeds reported earnings: $4.44 annual cost versus ~$4.12 underlying EPS, creating a structural deficit that relies on FCF, accounting choices, and buybacks
• Management has funded every dividend raise with pricing realization above 4% annually—a single point of failure
• Next year's cash demand rises to ~$7.3B after 5% dividend raise, compressing the buffer further
• Ste. Michelle Wine sale inflated 2024 results; underlying earnings power is ~$4.12 EPS
• NJOY impairment is the third major smokeless pivot failure (including JUUL)—a pattern of capital misallocation rather than pruning
• FDA lawsuit is binary with asymmetric downside: negative outcome "collapses" the reduced-risk product thesis, not just "flips" to underappreciated growth
• Pricing power of 4.5% realization is not permanent—recession, excise tax increases, or menthol ban break the inelasticity assumption
• Polymarket pricing 10% recession odds; recession probabilities spike without warning and hit both volume decline and pricing power simultaneously
• 95% no-cut probability is already priced into current price; MO's 6% yield is appropriate compensation, not undervalued
• If Fed surprises hawkish, MO gets crushed as dividend stocks aren't immune to equity selloff; if dovish, MO loses yield advantage—no double tailwind scenario exists
• ATR compressed from 2.15 to 1.47—volatility contraction precedes breakouts AND breakdowns; direction is unknown
• MACD histogram rolled from 0.534 to 0.366 while price rose—textbook momentum divergence
• RSI walked from 32 to 61 and is fading back to 59—trend is maturing, not strengthening
• Adding above $70.50 into resistance with $68.20 stop (barely 2% below) provides zero margin of safety
• $68.20 stop gets blown through by any single bad day, FDA ruling, or soft Q3 preannouncement
• P/E of 14.7x trailing, 11.9x forward, with PEG of 2.69 due to no growth compensation—cheapness is accurate discounting of structural decline, not mispricing
• BAT comparison reveals MO is preferred on growth, valuation, and smokeless momentum—the "discount" has structural justification
• Social sentiment 6.2/10 bullish with zero retail chatter resembles prior yield trap profiles where institutions dump first when dividend is questioned
• October 9 dividend payment is a scheduled non-event, not a market-moving catalyst

→ vs aggressive: FCF coverage of 1.30x is not "healthy with room to maneuver"—the ~$2B buffer is insufficient to cover capex, debt service, working capital, and any operational missteps before tapping debt or buybacks to fund the dividend

→ vs aggressive: Pricing in positive FDA binary outcome as base case is dangerous—the market should price in the negative outcome given an FDA that has consistently tightened regulations on reduced-risk products

→ vs aggressive: Inelastic demand assumption is the "most dangerous part of the bullish case"—recession, excise tax increases, or menthol ban break both pricing power AND volume simultaneously, not sequentially

→ vs aggressive: 95% no-cut probability is already consensus and priced into the current price—the macro tailwind is already in the multiple, not an asymmetric catalyst

→ vs aggressive: ATR compression does not "precede breakouts" exclusively—it also precedes breakdowns, and calling the current setup "confirmation" of a breakout is how you buy the top of a Bollinger Band rejection

→ vs aggressive: MACD histogram rolling from 0.534 to 0.366 while price rises is textbook momentum divergence, not "healthy profit-taking"—this rationalization turns technical warnings into entry signals

→ vs aggressive: Treating the October 9 dividend payment as a market-moving catalyst is incorrect—it is a scheduled, predictable cash transfer, not an event

→ vs aggressive: The BAT comparison is a "major structural warning"—when peers are preferred on growth, valuation, and smokeless momentum, the discount reflects accurate structural decline, not mispricing

HOLD current position; add on pullback to $68.20-68.50 or breakout retest above $70.50; maintain $68.20 stop; trim on false break above $70.50

• Normalized EPS is $4.75-5.00, covering $4.44 dividend at 1.07x coverage (workable, not comfortable)
• 30% FCF buffer is adequate contingent on pricing realization staying above 4%
• Dividend is 'funded but not fortified' — single point of failure is pricing power sustainability
• ATR compressed from 2.15 to 1.47; MACD histogram diverged from 0.534 to 0.366
• Resistance at $70.44-$70.50 (upper Bollinger Band); support at $68.20 (50 SMA, 10 EMA)
• Add level: pullback to $68.20-68.50 zone (trend support with momentum reset) OR confirmed breakout-and-retest above $70.50
• Stop loss at $68.20 is tight but appropriate at ~1 ATR for a 0.49-beta defensive name
• Q2 miss with 9% single-day drawdown; Q3 reporting ~6 weeks away with real pre-announcement risk
• FDA lawsuit adds optionality but should not drive position sizing
• MO fairly valued relative to history, modestly cheap vs defensive peers; 6.3% yield compensates for structural risks
• Trade-down dynamics benefited MO in 2008-2009 recession; recession risk partially offset by discount exposure
• PEG of 2.69 is elevated but MO warrants quality premium over pure yield peers

→ vs aggressive: Adding at $70.50+ resistance with tight $68.20 stop yields only 5% upside vs 3% downside risk — poor risk-reward and tactical overconfidence

→ vs aggressive: Q2 miss with 9% drawdown and Q3 reporting ~6 weeks away argues against adding into resistance regardless of macro/technical setup

→ vs conservative: Waiting for pullback that may never come in a volatility-compressed name leaves money on the table in the other direction

→ vs conservative: $68.20 stop being 'tight' is misframed — $1.50 stop on $69.70 entry is exactly 1 ATR for a 0.49-beta defensive name

→ vs conservative: Recession 'breaks both pricing and volume at once' is empirically shaky; MO held up in 2008-09 on trade-down dynamics

→ vs conservative: FDA lawsuit likely produces procedural delay rather than substantive win; adds optionality but doesn't change base case